Early loss of measles antibodies after MMR vaccine among HIV-infected adults receiving HAART

Vaccine

Volumn 27, Issue 50, 2009, Pages 7059-7064

  Belaunzarán Zamudio, Pablo F ^a   García León, Miguel L ^b   Wong Chew, Rosa María ^b   Villasís Keever, Angelina ^a   Cuellar Rodríguez, Jennifer ^a   Mosqueda Gómez, Juan L ^c   Muñoz Trejo, Teresa ^a   Escobedo, Kenia ^a   Santos, José I ^b   Ruiz Palacios, Guillermo M ^a   Sierra Madero, Juan G ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c UNIVERSITY OF GUANAJUATO   (Mexico)

Author keywords

HIV; Immunization; Measles

Indexed keywords

MEASLES ANTIBODY; MEASLES MUMPS RUBELLA VACCINE;

ADULT; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ERUPTION; DRUG FEVER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; MALE; MEASLES; MEASUREMENT; MUMPS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RUBELLA; VACCINATION;

ADULT; ANTIBODIES, VIRAL; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CELL PROLIFERATION; CROSS-SECTIONAL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HIV INFECTIONS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; MALE; MEASLES; MEASLES-MUMPS-RUBELLA VACCINE; MEXICO; PROSPECTIVE STUDIES; SEROEPIDEMIOLOGIC STUDIES; YOUNG ADULT;

EID: 70449107049     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.09.063     Document Type: Article

References (58)

1. Freedman D.O. Advising travelers with specific needs. In: Arguin P.M., Kozarsky P.E., and Reed C. (Eds). Centers for Disease Control and Prevention. Health Information for International Travel 2008 (2008), Elsevier, Philadelphia
2. WHO. Measles Vaccines. Weekly Epidemiological Record 2004; 79:129-144.
3. Anonimous. Recommended Adult Immunization Schedule - United States, October 2007-September 2008. MMWR 2007 October 19;56(41):Q1-Q4.
4. Lepage P., Dabis F., Msellati P., Hitimana D.G., Stevens A.M., Mukamabano B., et al. Safety and immunogenicity of high-dose edmonston-zagreb measles vaccine in children with HIV-1 Infection. A cohort study in Kigali, Rwanda. Am J Dis Child 146 (1992) 550-555
5. Cutts F.T., Mandala K., St Louis M., Brown C., Mayala B., Zell E.R., et al. Immunogenicity of high-titer edmonston-zagreb measles vaccine in human immunodeficiency virus-infected children in Kinshasa, Zaire. J Infect Dis 167 (1993) 1418-1421
6. Krasinski K., and Borkowsky W. Measles and measles immunity in children infected with human immunodeficiency virus. JAMA 261 (1989) 2512-2516
7. Moss W.J., Clements C.J., and Halsey N.A. Immunization of children at risk of infection with human immunodeficiency virus. Bull World Health Organ 81 (2003) 61-70
8. Advisory Comitee on Immunization Practices. Measles, Mumps, and Rubella -Vaccine Use and Strategies for Elimination of Measles, Rubella, and Congenital Rubella Syndrome and Control of Mumps: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1998 May 22;47(RR-8):1-67.
9. Secretaria de Salud M. NORMA Oficial Mexicana NOM-036-SSA2-2002, Prevención y control de enfermedades. Aplicación de vacunas, toxoides, sueros, antitoxinas e inmunoglobulinas en el humano. 2002 August 21;NOM-036-SSA2-2002.
10. Moss W.J., Scott S., Mugala N., Ndhlovu Z., Beeler J.A., Audet S.A., et al. Immunogenicity of standard-titer measles vaccine in HIV-1-infected and uninfected Zambian children: an observational study. J Infect Dis 196 (2007) 347-355
11. Moss W.J., and Griffin D.E. Global measles elimination. Nat Rev Microbiol 4 (2006) 900-908
12. Biellik R., Madema S., Taole A., Kutsulukuta A., Allies E., Eggers R., et al. First 5 years of measles elimination in southern Africa: 1996-2000. Lancet 359 9317 (2002) 1564-1568
13. Helfand R.F., Witte D., Fowlkes A., Garcia P., Yang C., Fudzulani R., et al. Evaluation of the immune response to a 2-dose measles vaccination schedule administered at 6 and 9 months of age to HIV-infected and HIV-uninfected children in Malawi. J Infect Dis 198 (2008) 1457-1465
14. Arpadi S.M., Markowitz L.E., Baughman A.L., Shah K., Adam H., Wiznia A., et al. Measles antibody in vaccinated human immunodeficiency virus type 1-infected children. Pediatrics 97 (1996) 653-657
15. Palumbo P., Hoyt L., Demasio K., Oleske J., and Connor E. Population-based study of measles and measles immunization in human immunodeficiency virus-infected children. Pediatr Infect Dis J 11 (1992) 1008-1014
16. Thaithumyanon P., Punnahitananda S., Thisyakorn U., Praisuwanna P., and Ruxrungtham K. Immune responses to measles immunization and the impacts on HIV-infected children. Southeast Asian J Trop Med Public 31 (2000) 658-662
17. Wallace M.R., Hooper D.G., Graves S.J., and Malone J.L. Measles seroprevalence and vaccine response in HIV-infected adults. Vaccine 12 (1994) 1222-1224
18. Markowitz L.E., Chandler F.W., Roldan E.O., Saldana M.J., Roach K.C., Hutchins S.S., et al. Fatal measles pneumonia without rash in a child with AIDS. J Infect Dis 158 (1988) 480-483
19. Good R.A., and Zak S.J. Disturbances in gamma globulin synthesis as experiments of nature. Pediatrics 18 (1956) 109-149
20. van Binnendijk R.S., Poelen M.C., van Amerongen G., de Vries P., and Osterhaus A.D. Protective immunity in macaques vaccinated with live attenuated, recombinant, and subunit measles vaccines in the presence of passively acquired antibodies. J Infect Dis 175 (1997) 524-532
21. SSA. Comunicado de Prensa No. 137, SSA México, 29 de junio de 2004.
22. UNAIDS/WHO epidemiological fact sheets on HIV/AIDS and Sexually Transmitted Infections, 2004 Update, Mexico; 2004.
23. Jokinen S., Osterlund P., Julkunen I., and Davidkin I. Cellular immunity to mumps virus in young adults 21 years after measles-mumps-rubella vaccination. J Infect Dis 196 (2007) 861-867
24. Huang C.L., Yang Y.H., Wang L.C., Lin Y.T., Tsai Y.Y., and Chiang B.L. Humoral and cellular immune response after measles vaccination in Taiwan. J Microbiol Immunol Infect 38 (2005) 169-175
25. Wong-Chew R.M., Islas-Romero R., Garcia-Garcia Mde L., Beeler J.A., Audet S., Santos-Preciado J.I., et al. Induction of cellular and humoral immunity after aerosol or subcutaneous administration of Edmonston-Zagreb measles vaccine as a primary dose to 12-month-old children. J Infect Dis 189 (2004) 254-257
26. Bautista-López N., Ward B.J., Mills E., McCormick D., Martel N., and Ratnam S. Development and durability of measles antigen-specific lymphoproliferative response after MMR vaccination. Vaccine 18 (2000) 1393-1401
27. Gans H., Yasukawa L., Rinki M., DeHovitz R., Forghani B., Beeler J., et al. Immune responses to measles and mumps vaccination of infants at 6, 9 and 12 months. J Infect Dis 184 (2001) 817-826
28. Wong-Chew R.M., Beeler J.A., Audet S., and Santos J.I. Cellular and humoral immune responses to measles in immune adults re-immunized with measles vaccine. J Med Virol 70 (2003) 276-280
29. Bekker V., Scherpbier H., Pajkrt D., Jurriaans S., Zaaijer H., and Kuijpers T.W. Persistent humoral immune defect in highly active antiretroviral therapy-treated children with HIV-1 infection: loss of specific antibodies against attenuated vaccine strains and natural viral infection. Pediatrics 118 (2006) e315-e322
30. Lowther S.A., Curriero F.C., Kalish B.T., Shields T.M., Monze M., and Moss W.J. Population immunity to measles virus and the effect of HIV-1 infection after a mass measles vaccination campaign in Lusaka, Zambia: a cross-sectional survey. Lancet (2009) e1025-e1032
31. Malaspina A., Moir S., Orsega S.M., Vasquez J., Miller N.J., Donoghue E.T., et al. Compromised B cell responses to influenza vaccination in HIV-infected individuals. J Infect Dis 191 (2005) 1442-1450
32. Nielsen H., Kvinesdal B., Benfield T.L., Lundgren J.D., and Konradsen H.B. Rapid loss of specific antibodies after pneumococcal vaccination in patients with human immunodeficiency virus-1 infection. Scand J Infect Dis 30 (1998) 597-601
33. Obaro S., Pugatch D., and Luzuriaga K. Immunogenicity and efficacy of childhood vaccines in HIV-1-infected children. The Lancet Infect Dis 4 (2004) 510-518
34. Titanji K., Chiodi F., Bellocco R., Schepis D., Osorio L., Tassandin C., et al. Primary HIV-1 infection sets the stage for important B lymphocyte dysfunctions. AIDS 19 (2005) 1947-1955
35. Levesque M.C., Moody M.A., Hwang K., Marshall D.J., Whitesides J.F., Amos J.D., et al. Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. PLoS Med 6 (2009) e1000107 10.1371/journal.pmed.1000107
36. Jiang W., Lederman M.M., Mohner R.J., Rodriguez B., Nedrich T.M., Harding C.V., et al. Impaired naive and memory B cell responsiveness to TLR9 stimulation in human immunodeficiency virus infection. J Virol 82 (2008) 7837-7845
37. De Milito A., Morch C., Sonnerborg A., and Chiodi F. Loss of memory (CD27) B lymphocytes in HIV-1 infection. AIDS 15 (2001) 957-964
38. Titanji K., De Milito A., Cagigi A., Thorstensson R., Grützmeier S., Atlas A., et al. Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection. Blood 108 (2006) 1580-1587
39. Hart M., Steel A., Clark S.A., Moyle G., Nelson M., Henderson D.C., et al. Loss of discrete memory B cell subsets is associated with impaired immunization responses in HIV-1 infection and may be a risk factor for invasive pneumococcal disease. J Immunol 178 (2007) 8212-8220
40. Lederman M.M., Connick E., Landay A., Kuritzkes D.R., Spritzler J., St Clair M., et al. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis 178 (1998) 70-79
41. Aurpibul L., Puthanakit T., Sirisanthana T., and Sirisanthana V. Response to measles, mumps, and rubella revaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy. Clin Infect Dis 45 (2007) 637-642
42. Melvin A.J., and Mohan K.M. Response to immunization with measles, tetanus, and Haemophilus influenzae type B vaccines in children who have human immunodeficiency virus type 1 infection and are treated with highly active antiretroviral therapy. Pediatrics 111 6 Pt 1 (2003) e641-e644
43. Berkelhamer S., Borock E., Elsen C., Englund J., and Johnson D. Effect of highly active antiretroviral therapy on the serological response to additional measles vaccinations in human immunodeficiency virus-infected children. Clin Infect Dis 32 (2001) 1090-1094
44. Hilgartner M., Maeder M.A., Mahoney E.M., Donfield S.M., Evatt B.L., Hoots W.K., and Hemophilia Growth and Development Study. Response to measles, mumps, and rubella revaccination among HIV-positive and HIV-negative children and adolescents with hemophilia. Am J Hematol 66 (2001) 92-98
45. Sprauer M.A., Markowitz L.E., Nicholson J.K., Holman R.C., Deforest A., Dales L.G., et al. Response of human immunodeficiency virus-infected adults to measles-rubella vaccination. J Acquir Immune Defic Syndr 6 (1993) 1013-1016
46. Ward B.J., Boulianne N., Ratnam S., Guiot M.C., Couillard M., and De Serres G. Cellular immunity in measles vaccine failure: demonstration of measles antigen-specific lymphoproliferative responses despite limited serum antibody production after revaccination. J Infect Dis 172 (1995) 1591-1595
47. Ovsyannikova I.G., Dhiman N., Jacobson R.M., Vierkant R.A., and Poland G.A. Frequency of measles virus-specific CD4+ and CD8+ T cells in subjects seronegative or highly seropositive for measles vaccine. Clin Diagn Lab Immunol 10 (2003) 411-416
48. Gans H.A., Yasukawa L.L., Alderson A., Rinki M., DeHovitz R., Beeler J., et al. Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States. J Infect Dis 190 (2004) 83-90
49. Lange C.G., Xu Z., Patterson B.K., Medvik K., Harnisch B., Asaad R., et al. Proliferation responses to HIVp24 during antiretroviral therapy do not reflect improved immune phenotype or function. AIDS 18 (2004) 605-613
50. Perry R.T., and Halsey N.A. The clinical significance of measles: a review. J Infect Dis 189 Suppl 1 (2004) S4-S16
51. Angel J.B., Walpita P., Lerch R.A., Sidhu M.S., Masurekar M., DeLellis R.A., et al. Vaccine-associated measles pneumonitis in an adult with AIDS. Ann Intern Med 129 2 (1998) 104-106
52. Orduña-Estrada P, Castañón-Arreola M, López-Bárcena J ea. Prevalencia de Anticuerpos contra Sarampión y Rubeóla en Adolescentes Inmunizados Enf Inf Microbiol 2004; 24(Suppl 1):s73.
53. Santos J.I., Nakamura M.A., Godoy M.V., Kuri P., Lucas C.A., and Conyer R.T. Measles in Mexico, 1941-2001: Interruption of endemic transmission and lessons learned. J Infect Dis 189 Suppl 1 (2004) S243-S250
54. Anonimous. Measles and Rubella Surveillance in The Americas. Age Dstribution of Measles Cases Mexico, December 2005-March 2006. PAHO 2006;Week 4 march 2006. Available at: http://www.paho.org/english/ad/fch/im/sme1209.pdf.
55. Sha B.E., Harris A.A., Benson C.A., Atkinson W.L., Urbanski P.A., Stewart J.A., et al. Prevalence of measles antibodies in asymptomatic human immunodeficiency virus-infected adults. J Infect Dis 164 (1991) 973-975
56. Kemper C.A., Zolopa A.R., Hamilton J.R., Fenstersheib M., Bhatia G., and Deresinski S.C. Prevalence of measles antibodies in adults with HIV infection: possible risk factors of measles seronegativity. AIDS 6 (1992) 1321-1325
57. Beverly E.S., Harris A., and Benson C.A. Prevalence of measles antibodies in asymptomatic human immunodeficiency virus-infected adults. J Infect Dis 164 (1991) 973-975
58. van den Hof S., van Gageldonk-Lafeber A.B., van Innendjik R.S., van Galgeldonk P.G.M., and Berbers G.A.M. Comparison of measles virus-specific antibody titres as measured by enzyme-linked immunosorbent assay and virus neutralization assay. Vaccine 21 (2003) 4210-4214